165 related articles for article (PubMed ID: 19761738)
1. Economic consequences to society of pandemic H1N1 influenza 2009 - preliminary results for Sweden.
Brouwers L; Cakici B; Camitz M; Tegnell A; Boman M
Euro Surveill; 2009 Sep; 14(37):. PubMed ID: 19761738
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.
Khazeni N; Hutton DW; Garber AM; Hupert N; Owens DK
Ann Intern Med; 2009 Dec; 151(12):829-39. PubMed ID: 20008759
[TBL] [Abstract][Full Text] [Related]
3. Summaries for patients. Assessing the best way to prevent spread of influenza.
Ann Intern Med; 2009 Dec; 151(12):I31. PubMed ID: 20008744
[No Abstract] [Full Text] [Related]
4. Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience.
Sander B; Bauch CT; Fisman D; Fowler RA; Kwong JC; Maetzel A; McGeer A; Raboud J; Scales DC; Gojovic MZ; Krahn M
Vaccine; 2010 Aug; 28(38):6210-20. PubMed ID: 20643091
[TBL] [Abstract][Full Text] [Related]
5. A tool for the economic analysis of mass prophylaxis operations with an application to H1N1 influenza vaccination clinics.
Cho BH; Hicks KA; Honeycutt AA; Hupert N; Khavjou O; Messonnier M; Washington ML
J Public Health Manag Pract; 2011; 17(1):E22-8. PubMed ID: 21135651
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemic.
Khazeni N; Hutton DW; Garber AM; Owens DK
Ann Intern Med; 2009 Dec; 151(12):840-53. PubMed ID: 20008760
[TBL] [Abstract][Full Text] [Related]
7. Public Health Measures in an Influenza Pandemic - the importance of surveillance.
Nicoll A; ; Ciancio B; de la Hoz KF; Kreidl P; Needham H; Varela C; Vasconcelos P; Webber JT; Wurz A
Euro Surveill; 2007 Nov; 12(11):E071101.4. PubMed ID: 17997909
[No Abstract] [Full Text] [Related]
8. Cost analysis of influenza vaccine administration in Fayette County, Kentucky, 2005-2007.
Kryscio KE
Public Health Rep; 2010; 125(2):358-63. PubMed ID: 20297765
[No Abstract] [Full Text] [Related]
9. Quantifying the economic value and quality of life impact of earlier influenza vaccination.
Lee BY; Bartsch SM; Brown ST; Cooley P; Wheaton WD; Zimmerman RK
Med Care; 2015 Mar; 53(3):218-29. PubMed ID: 25590676
[TBL] [Abstract][Full Text] [Related]
10. Total Economic Consequences of an Influenza Outbreak in the United States.
Prager F; Wei D; Rose A
Risk Anal; 2017 Jan; 37(1):4-19. PubMed ID: 27214756
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.
Newall AT; Wood JG; Oudin N; MacIntyre CR
Emerg Infect Dis; 2010 Feb; 16(2):224-30. PubMed ID: 20113551
[TBL] [Abstract][Full Text] [Related]
12. Stagnating influenza vaccine coverage rates among high-risk groups in Poland and Sweden in 2003/4 and 2004/5.
Kroneman MW; van Essen GA
Euro Surveill; 2007 Apr; 12(4):E1-2. PubMed ID: 17991383
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness study on influenza prevention in Hong Kong.
Fitzner KA; Shortridge KF; McGhee SM; Hedley AJ
Health Policy; 2001 Jun; 56(3):215-34. PubMed ID: 11399347
[TBL] [Abstract][Full Text] [Related]
14. Mitigation of pandemic influenza: review of cost-effectiveness studies.
Lugnér AK; Postma MJ
Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):547-58. PubMed ID: 19941432
[TBL] [Abstract][Full Text] [Related]
15. Cost comparison of 2 mass vaccination campaigns against influenza A H1N1 in New York City.
Kansagra SM; McGinty MD; Morgenthau BM; Marquez ML; Rosselli-Fraschilla A; Zucker JR; Farley TA
Am J Public Health; 2012 Jul; 102(7):1378-83. PubMed ID: 22676501
[TBL] [Abstract][Full Text] [Related]
16. [Influenza--old medical problem].
Brydak LB
Przegl Epidemiol; 2006; 60 Suppl 1():23-7. PubMed ID: 16909771
[TBL] [Abstract][Full Text] [Related]
17. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries.
Ryan J; Zoellner Y; Gradl B; Palache B; Medema J
Vaccine; 2006 Nov; 24(47-48):6812-22. PubMed ID: 17034909
[TBL] [Abstract][Full Text] [Related]
18. Risk groups and other target groups - preliminary ECDC guidance for developing influenza vaccination recommendations for the season 2010-11.
Nokleby H; Nicoll A
Euro Surveill; 2010 Mar; 15(12):. PubMed ID: 20350496
[TBL] [Abstract][Full Text] [Related]
19. [Well-functioning strategy for the A/H1N1 pandemic in Varmland. A preliminary summary].
Wik O
Lakartidningen; 2010 Jun 16-29; 107(24-25):1630-3. PubMed ID: 20687426
[No Abstract] [Full Text] [Related]
20. From the patient perspective: the economic value of seasonal and H1N1 influenza vaccination.
Lee BY; Bacon KM; Donohue JM; Wiringa AE; Bailey RR; Zimmerman RK
Vaccine; 2011 Mar; 29(11):2149-58. PubMed ID: 21215340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
